Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ALXO
stocks logo

ALXO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.362
-34.09%
--
--
-0.315
-45.69%
--
--
-0.300
-38.78%
Estimates Revision
Stock Price
Go Up
up Image
+12.30%
In Past 3 Month
Wall Street analysts forecast ALXO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALXO is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ALXO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALXO is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.370
sliders
Low
2.00
Averages
3.00
High
4.00
Current: 1.370
sliders
Low
2.00
Averages
3.00
High
4.00
Jefferies
NULL -> Buy
initiated
$4
2025-11-13
Reason
Jefferies
Price Target
$4
2025-11-13
initiated
NULL -> Buy
Reason
Jefferies initiated coverage of ALX Oncology with a Buy rating and $4 price target. ALX has strategically focused on two lead programs, Evorpacept in post-ENHERTU HER2+ mBC using prospective CD47 enrichment, supported by "encouraging" gastric data and ALX2004, an ADC with a differentiated design for wider therapeutic window in solid tumors, the analyst tells investors.
UBS
Buy
downgrade
$1
2025-05-21
Reason
UBS
Price Target
$1
2025-05-21
downgrade
Buy
Reason
UBS lowered the firm's price target on ALX Oncology to $1 from $1.20 and keeps a Buy rating on the shares.
H.C. Wainwright
Buy
downgrade
$5 -> $2
2025-05-09
Reason
H.C. Wainwright
Price Target
$5 -> $2
2025-05-09
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on ALX Oncology to $2 from $5 and keeps a Buy rating on the shares. The company announced its decision to discontinue the development of evorpacept in gastric and gastroesophageal cancers based on the FDA's feedback, the analyst tells investors in a research note.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$5
2025-03-07
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$5
2025-03-07
Reiterates
Strong Buy
Reason
Stifel
Bradley Canino
Hold
Maintains
$3 → $1.5
2025-03-07
Reason
Stifel
Bradley Canino
Price Target
$3 → $1.5
2025-03-07
Maintains
Hold
Reason
Stifel lowered the firm's price target on ALX Oncology to $1.50 from $3 and keeps a Hold rating on the shares. Following a R&D day and the company's Q4 report, the firm updated its model for the quarter, restructuring, and updated cash guidance, but has reduced its odds of success and confidence in gastric cancer and awaits proof of concept data in additional tumor type regimens.
Jefferies
Michael Yee
Hold
to
Strong Buy
Upgrades
$2 → $3
2025-03-06
Reason
Jefferies
Michael Yee
Price Target
$2 → $3
2025-03-06
Upgrades
Hold
to
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for ALX Oncology Holdings Inc (ALXO.O) is -1.10, compared to its 5-year average forward P/E of -8.54. For a more detailed relative valuation and DCF analysis to assess ALX Oncology Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.54
Current PE
-1.10
Overvalued PE
4.27
Undervalued PE
-21.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.92
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
5.09
Undervalued EV/EBITDA
-16.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
-344.11
Current PS
0.00
Overvalued PS
11352.52
Undervalued PS
-12040.74
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ALXO News & Events

Events Timeline

(ET)
2025-11-07
08:23:20
ALX Oncology projects sufficient cash reserves to last until the first quarter of 2027.
select
2025-11-07
08:22:57
ALX Oncology Announces Q3 Earnings Per Share of 41 Cents, Exceeding Consensus Estimate of 37 Cents
select
2025-10-23 (ET)
2025-10-23
12:41:34
ALX unveils preclinical findings and ongoing Phase 1 trial for ALX2004
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-19Globenewswire
Targeted Cancer Treatments Accelerate as Precision Medicine Market Exceeds $106 Billion

  • Precision Oncology Market Growth: The precision oncology sector is rapidly evolving, with the market reaching $106.21 billion in 2025 and projected to grow to $158.9 billion by 2029, driven by advancements in biomarker-driven therapies and immunotherapy modalities.

  • Oncolytics Biotech's Pivotal Trial: Oncolytics Biotech has received FDA alignment for its Phase 3 study of pelareorep in pancreatic cancer, aiming to provide the first immunotherapy option for this indication, with promising preliminary data showing significant response rates.

  • ALX Oncology's Clinical Success: ALX Oncology reported a 65% objective response rate for its candidate evorpacept in treating high CD47-expressing HER2-positive gastric cancer, significantly outperforming standard therapies and guiding future clinical strategies.

  • Innovations from Other Biotech Firms: Companies like Erasca, Immuneering, and Prelude Therapeutics are advancing their respective therapies and programs, with notable achievements in patent protections and promising clinical trial results, indicating a strong pipeline in the oncology sector.

[object Object]
Preview
1.0
11-19Newsfilter
ALX Oncology to Showcase at Upcoming Investor Events

  • Company Participation in Conferences: ALX Oncology will participate in the Jefferies Global Healthcare Conference in London on November 19, 2025, and the Piper Sandler 37th Annual Global Healthcare Conference in New York on December 3, 2025, both featuring fireside chat formats.

  • Webcast Availability: Webcasts for both conferences will be accessible through the Investors section of ALX Oncology's website, with replays available for up to 90 days after the events.

  • About ALX Oncology: ALX Oncology is a clinical-stage biotechnology company focused on developing novel cancer therapies, including its lead candidate, evorpacept, which is undergoing multiple clinical trials.

  • Pipeline Development: The company is also advancing a second candidate, ALX2004, an EGFR-targeted antibody-drug conjugate, which began Phase 1 trials in August 2025.

[object Object]
Preview
9.0
11-07SeekingAlpha
ALX Oncology Projects $2B–$4B Market Potential for HER2/CD47 Breast Cancer as It Advances Biomarker-Driven Approaches

  • Management Insights: CEO Jason Lettmann highlighted the promising results from the ASPEN-06 trial, indicating that high CD47 expression is a key predictive biomarker for evorpacept's efficacy in HER2-positive gastric cancer, with a reported 41% overall response rate (ORR) in the treatment arm.

  • Clinical Development: The company is on track to initiate a Phase II trial in breast cancer this quarter, focusing on a biomarker-driven strategy, while also progressing with ALX2004, expecting initial safety data in the first half of 2026.

  • Financial Position: ALX Oncology reported a cash balance of $67 million, providing a financial runway into Q1 2027, with no additional financial figures disclosed during the call.

  • Analyst Sentiment: Analysts expressed positive sentiment regarding the company's biomarker strategy and clinical data, with management demonstrating increased confidence and clarity in their development plans compared to previous quarters.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ALX Oncology Holdings Inc (ALXO) stock price today?

The current price of ALXO is 1.37 USD — it has increased 3.79 % in the last trading day.

arrow icon

What is ALX Oncology Holdings Inc (ALXO)'s business?

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.

arrow icon

What is the price predicton of ALXO Stock?

Wall Street analysts forecast ALXO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALXO is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ALX Oncology Holdings Inc (ALXO)'s revenue for the last quarter?

ALX Oncology Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is ALX Oncology Holdings Inc (ALXO)'s earnings per share (EPS) for the last quarter?

ALX Oncology Holdings Inc. EPS for the last quarter amounts to -0.41 USD, decreased -29.31 % YoY.

arrow icon

What changes have occurred in the market's expectations for ALX Oncology Holdings Inc (ALXO)'s fundamentals?

The market is revising No Change the revenue expectations for ALXO for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 12.30%.
arrow icon

How many employees does ALX Oncology Holdings Inc (ALXO). have?

ALX Oncology Holdings Inc (ALXO) has 80 emplpoyees as of December 05 2025.

arrow icon

What is ALX Oncology Holdings Inc (ALXO) market cap?

Today ALXO has the market capitalization of 74.28M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free